The global prevalence of non-alcoholic fatty liver disease (NAFLD) is an estimated 25%. There is a recognised correlation between the development of fatty deposits in the liver and chronically elevated serum alanine transaminase (ALT). NAFLD may progress to non-alcoholic steatohepatitis (NASH), characterised by liver inflammation and a risk factor for future liver cirrhosis, failure and malignancy. Risk factors for the development of NAFLD include diabetes, metabolic syndrome and obesity, though seemingly healthy individuals can also develop NAFLD idiopathically.